IGF-1 LR3 Research Findings: What Preclinical Studies Report
2026-08-01 · 5 min
This article summarizes how IGF-1 LR3, a long-acting analog of insulin-like growth factor 1, has been studied in the research literature. All findings below come from laboratory and animal models and are not claims about effects in people.
What the research has looked at
- Extended half-life. The LR3 modification is studied specifically for reduced binding to carrier proteins, extending activity in research models.
- Cell-culture research. IGF-1 is a common reagent in cell-culture work examining growth and proliferation pathways.
- Signaling studies. Research has characterized the analog's interaction with IGF-1 receptor signaling.
What people report anecdotally
Anecdotally, people in online fitness communities often discuss IGF-1 LR3 in the context of muscle growth and recovery. These are unverified accounts from third parties, not us. They are not effects we have tested or observed, and we cannot promise any of them.
How to read these findings
These observations come from controlled laboratory settings, including routine cell-culture use. They do not establish outcomes in humans. IGF-1 LR3 is supplied as a research compound only.
Related reading
See the research catalog for related growth-factor compounds. Every batch is third-party lab-tested with a COA.
Research use only. This article summarizes laboratory and research-model information only. It is not medical advice and not guidance for human use. Products are not for human or animal consumption.